REVENIO

Revenio Group Corporation: Interim report

January 1 – September 30, 2026



© Revenio 2026

Contents

Summary 3
Key consolidated figures 4
Financial guidance for 2026 6
Comments from CEO Jouni Toijala 7
Strategy 9
Net sales, profitability and profit 11
Balance sheet, financial position and cash flow 13
Risks and uncertainties 14
Major shareholders 16
Key events in the review period 17
Events after the review period 17
Alternative key figures 18
Accounting policies 21
Tables 22



Revenio Group Corporation: Interim report January 1 – September 30, 2026
Q3/2026: New strategy launched, integration advancing according to plan

The figures in parentheses refer to the corresponding period in the previous year unless otherwise stated.

Revenio acquired the entire share capital of the Visionix International Group (“Visionix”) from its parent company, LT International SAS.

Visionix has been consolidated into Revenio as of June 2026.

July–September 2026

- Net sales totaled EUR 58.8 (25.9) million, up by 127.5%
- The currency-adjusted increase of net sales was 125.5%
- Adjusted EBITDA was EUR 10.2 (7.4) million, or 17.4% of net sales, up by 38.9%
- Adjusted EBITA was EUR 8.7 (6.6) million, or 14.7% of net sales, up by 30.3%
- EBITDA was EUR 7.3 (7.2) million, or 12.3% of net sales, up by 1.4%
- EBITA was EUR 5.7 (6.4) million, or 9.7% of net sales, down by 11.7%
- Cash flow from operating activities totaled EUR 5.5 (3.0) million
- Earnings per share came to EUR 0.116 (0.173)
- The integration of Visionix has progressed as planned, and Revenio aims to reach 70 per cent of the estimated EUR 20 million synergies by the end of 2027. Integration costs related mainly to the Visionix acquisition were approximately EUR 3.0 million during the quarter.
- In connection with the reporting for the review period, Revenio is updating its financial guidance for 2026; the exchange rate-adjusted net sales are estimated to be between EUR 190 million and EUR 200 million. The profitability guidance is unchanged.

January–September 2026


- Net sales totaled EUR 125.4 (78.5) million, up by 59.8%
- The currency-adjusted increase of net sales was 61.7%
- Adjusted EBITDA was EUR 24.9 (22.8) million, or 19.8% of net sales, up by 9.1%
- Adjusted EBITA was EUR 21.7 (20.7) million, or 17.3% of net sales, up by 4.7%
- EBITDA was EUR 15.0 (22.1) million, or 12.0% of net sales, down by 32.1%
- EBITA was EUR 11.8 (20.0) million, or 9.4% of net sales, down by 41.0%
- Cash flow from operating activities totaled EUR -0.3 (14.4) million
- Earnings per share came to EUR 0.231 (0.446)

Key consolidated figures


MEUR	7–9/2026	7–9/2025	Change-%	1–9/2026	1–9/2025	Change-%	1–12/2025
Net sales	58.8	25.9	127.5	125.4	78.5	59.8	109.7
Gross margin	37.2	18.5	101.1	81.3	56.7	43.3	77.8
Gross margin -%	63.2	71.5	-11.6	64.8	72.2	-10.3	70.9
EBITDA	7.3	7.2	1.4	15.0	22.1	-32.1	29.9
EBITDA -%	12.3	27.7	-55.4	12.0	28.2	-57.5	27.3
EBITA	5.7	6.4	-11.7	11.8	20.0	-41.0	27.1
EBITA -%	9.7	24.9	-61.2	9.4	25.5	-63.1	24.7
EBIT	3.6	6.0	-40.5	8.4	18.7	-55.4	25.4
Adjusted EBITDA	10.2	7.4	38.9	24.9	22.8	9.1	31.0
Adjusted EBITDA -%	17.4	28.5	-38.9	19.8	29.0	-31.7	28.3
Adjusted EBITA	8.7	6.6	30.3	21.7	20.7	4.7	28.3
Adjusted EBITA -%	14.7	25.7	-42.7	17.3	26.4	-34.5	25.8
Return on investment -%, ROI	1.5	5.3	-72.2	4.4	14.6	-70.2	20.8
Return on equity-%, ROE	2.2	4.2	-48.1	4.7	11.0	-56.7	15.7
Earnings per share	0.116	0.173		0.231	0.446		0.655
	Sep 30, 2026	**Sep 30, 2025**	**Change, %-point**				
Equity ratio-%	32.3	79.6	-47.3				
Gearing-%	149.3	-2.8	152.1				
Net debt / Adjusted EBITDA *	5.1	-0.1					

* Adjusted EBITDA in column Sep 30, 2026 is based on 2025 pro forma numbers and in column Sep 30, 2025 for historical 12-month values.


Net sales, M€



Adjusted EBITA, M€



Cash flow from operations, M€



Financial guidance for 2026



Revenio's specified financial guidance:

• Revenio Group's exchange rate-adjusted net sales are estimated to be between EUR 190 million and EUR 200 million and

• Adjusted EBITA -% is estimated to remain at a satisfactory level.

The lower end of the range assumes continued softness in market demand and slower customer activity. The upper end assumes an improvement in market conditions combined with successful execution of commercial initiatives.

Revenio's previous financial guidance, published on September 8, 2026:

Revenio Group's exchange rate-adjusted net sales are estimated to be between EUR 190 million and EUR 205 million and EBITA, excluding items affecting comparability is estimated to remain at a satisfactory level.

Comments from CEO Jouni Toijala

The third quarter of the year was Revenio's first full quarter together with Visionix and an important phase in building the combined company after the acquisition in May. We continued the integration work with determination and completed the strategy process launched in connection with the acquisition. At our Capital Markets Day held in September, we presented our updated strategy and new financial targets for 2027–2029. At the heart of our strategy is the shift from vision care towards connected eye health. Our broader product and service offering after the acquisition strengthens our ability to serve new customer groups, such as optical retail, and continue serving existing customers in optometry and ophthalmology with a more comprehensive product portfolio.

The integration of Visionix has progressed as planned, and we aim to reach 70 per cent of the estimated EUR 20 million synergies by the end of 2027. During the third quarter, we continued building a shared organization, operating models and culture, as well as harmonizing key business processes. We also implemented organizational changes in the United States by combining sales operations and clarifying the operating model in the region. The changes aim to strengthen our competitiveness and enhance our ability to capitalize on the commercial potential of our expanded product portfolio. In the next phases of integration, we will focus on improving our operational efficiency, realizing commercial synergies and continuing to strengthen our business processes.

Our net sales for the third quarter were EUR 58.8 million (25.9), representing growth of 127.5%. Organically, net sales development was flat. Net sales developed strongly particularly in the EMEA and LATAM region, driven by France, Italy and global customers. This was supported especially by demand for multimodal devices. In the APAC region, market conditions remained challenging. In North America, net sales declined organically from the comparison period, partly reflecting the impact of the reorganization of our regional sales and marketing teams. We believe the changes we have implemented will strengthen our sales execution and support improved commercial performance going forward. Our combined sales organization, which began operating in the United States in August, together with our expanded product portfolio, provides a strong foundation to strengthen our commercial activities going forward.



Comments from CEO Jouni Toijala

Our profitability in the third quarter was as we expected. From this quarter onwards, Visionix's lower margin profile is fully reflected in our quarterly figures. Adjusted EBITA was 14.7% and gross margin was 63.2% of net sales. Gross margin, in turn, was positively affected by tariff refunds related to the North American business. Our cash flow from operating activities returned to a clearly positive level and amounted to EUR 5.5 million. We have narrowed down our financial guidance top level to EUR 200 million, driven by softer market development.

One of the cornerstones of our updated strategy is advancing clinical confidence and workflow efficiency through integrated product innovations and workflows that help our customers provide better eye care. As a concrete example of this, in September we launched the next generation iCare IC1000 tonometer, which combines reliable intraocular pressure measurement with advanced GuideCam technology, anesthesia-free operation and completely automated digital workflow. We also achieved a significant commercial success in the UK by winning an NHS tender for imaging devices used in diabetic retinopathy screening. This opens up new opportunities for us, particularly in terms of increasing sales of our iCare DRSplus fundus imaging device.

The approximately EUR 80 million rights issue completed after the review period strengthened our financial position and supports the execution of our strategy. The offering was clearly oversubscribed, and we used the net proceeds to repay the bridge financing related to the Visionix acquisition. For us, the strong outcome of the rights issue is an important vote of confidence, and I would once again like to thank all our shareholders who participated in the offering.

We have now taken significant steps in building the combined company. Going forward, we will focus particularly on successfully executing the integration, capitalizing on the commercial opportunities offered by our expanded product portfolio and strengthening profitability. In this way, we are laying the foundation for Revenio's long-term value creation.

Jouni Toijala
CEO

Strategy 2027–2029: Leading the shift from vision care to connected eye health



Advance Clinical Confidence and Workflow Excellence
through connected product innovations and workflows that help customers deliver better eye care

Drive Commercial Excellence
through customer-focused go-to-market

Scale Operational Excellence
with uncompromising quality

Develop People & Culture
as a foundational strength

Continue sustainable and profitable growth

Net sales


Revenio generates net sales from eye care and ophthalmic diagnostic devices and equipment, including refraction, screening and diagnostic solutions, as well as related software and services. Revenio's key customer segments include optical retail, optometry and ophthalmology, as well as other healthcare segments, such as pharma, universities and primary care.

Revenio generates net sales globally, with its products available in more than 130 countries through a combination of its own sales network, distributors and OEM arrangements. Revenio sells its products directly to end-users in the United States and selected European countries, while other markets are primarily served through a global network of more than 400 distribution partners.

Net sales breakdown

Net sales by geographical area MEUR	7-9/2026	7-9/2025	Change, %	1-9/2026	1-9/2025	Change, %	2025	Pro forma 2025
North America	19.7	14.1	39.4%	47.3	38.7	22.2%	55.0	89.8
EMEA and LATAM	34.3	8.0	330.1%	64.5	26.3	145.7%	36.7	139.0
APAC	4.8	3.8	28.1%	13.5	13.5	0.2%	18.0	24.0
Total	**58.8**	**25.9**	**127.5%**	**125.4**	**78.5**	**59.8%**	**109.7**	**252.8**

Note: The unaudited pro forma financial information has been prepared to illustrate how the Visionix Transaction and related financing would have affected Revenio's consolidated comprehensive profit & loss statement had they been completed on 1 January 2025.



Organic net sales development

Organic net sales MEUR	7-9/2026	Pro forma 7-9/2025	Change, %	Pro forma 1-9/2026	Pro forma 1-9/2025	Change, %
Net sales	58.8	59.1	-0.5%	180.7	182.2	-0.8%
Effect of exchange rates	-0.3			2.6		
Net sales at comparable exchange rates	58.5	59.1	-1.0%	183.3	182.2	0.6%

Pro forma net sales include Visionix for the whole review period.

Net sales, profitability and profit

July–September 2026

Revenio Group's net sales July 1–September 30, 2026 was EUR 58.8 (25.9) million. Net sales increased by 127.5%. The currency-adjusted increase of net sales was 125.5%.

Gross margin-% reduced to 63.2 (71.5)% driven by approximately negative 9 percentage point Visionix dilution impact. The product mix and higher unit costs of electronic components had a 2%-points negative impact on the third quarter gross margin-%, which was offset by approximately 3%-points positive impact of tariff refunds related to the North American business.

The Group's adjusted EBITA was EUR 8.7 (6.6) million, or 14.7% of net sales, impacted positively by the increase in net sales and negatively by an increase in overall fixed costs. In addition, non-recurring expenses relating mainly to integration was EUR 3.0 million. Profit before income taxes was EUR 3.3 (6.0) million.

Earnings per was to EUR 0.116 (0.173). Equity per share was EUR 5.33 (4.08).

January–September 2026

Revenio Group's net sales January 1–September 30, 2026 was EUR 125.4 (78.5) million. Net sales increased by 59.8%. The currency-adjusted increase of net sales was 61.7%.

Gross margin-% reduced to 64.8 (72.2)% driven by approximately negative 4 percentage point Visionix dilution impact.

The Group's adjusted EBITA was EUR 21.7 (20.7) million, or 17.3% of net sales, impacted positively by the increase in net sales and negatively by an increase in overall fixed costs. In addition, non-recurring expenses relating mainly to integration was EUR 9.8 million. Profit before income taxes was EUR 8.8 (16.0) million.

Earnings per share was EUR 0.231 (0.446). Equity per was to EUR 5.33 (4.08).

Items affecting comparability

MEUR	7-9/2026	7-9/2025	1-9/2026	1-9/2025	2025
Expenses related to other strategic initiatives presented in other operating expenses	1.6	0.2	8.2	0.7	0.8
Expenses related to restructuring presented mainly in employee benefits expenses	1.4	0.0	1.6	0.0	0.3
Total	**3.0**	**0.2**	**9.8**	**0.7**	**1.1**

Balance sheet, financial position and cash flow

The Group's balance sheet totaled EUR 480.1 (137.0) million on September 30, 2026. The value of goodwill on the balance sheet totaled EUR 184.3 (62.8) million on September 30, 2026.

The Group's equity was EUR 155.1 (109.0) million. The Group's net debt at the end of the period totaled EUR 231.6 (-3.0) million, and net gearing was 149.3 (-2.8)%. The Group's equity ratio was 32.3 (79.6)%. The Group's liquid assets at the end of the review period on September 30, 2026 totaled EUR 17.2 (14.4) million. During Q3/2026 cash flow from operations grew to EUR 5.5 (3.0) million and was impacted by a positive change in working capital.

Revenio's liquidity position remained good during the reporting period. In connection with the acquisition of Visionix completed on 28 May 2026, the Group entered into a new financing arrangement comprising a EUR 130 million amortizing term loan facility with a maturity of four years and options to extend by up to 12 months, a EUR 80 million bridge-to-equity facility and a EUR 17 million vendor loan arrangement. In connection with the arrangement, Revenio repaid its existing bank loans with a nominal amount of EUR 3.8 million as of deal closing and Visionix's bank loans of EUR 58.3 million. The Group complies with all financing covenants and maintains sufficient liquidity for its operational and strategic needs.

The Annual General Meeting held on 12 May 2026 authorized the Board of Directors to resolve on a rights issue of up to 14,600,000 new shares. Revenio repaid the EUR 80 million bridge facility in full on 30 October 2026 using the net proceeds from the rights issue, in accordance with the financing agreement. Interest and fees related to the bridge financing totaled EUR 0.2 million and were paid in connection with the repayment.

In addition Revenio has a EUR 20 million revolving credit facility in use for general corporate purposes, of which EUR 19 million has been drawn.



Average number of personnel during the review period

	1-9/2026	1-9/2025	1-12/2025
North America	85	47	47
EMEA and LATAM	352	171	172
APAC	27	30	30
Total	**464**	**248**	**248**

At the end of the review period, the number of employees was 744 (248). Visionix has been consolidated into Revenio as of June 2026.

Risks and uncertainties

Risks Revenio Group is exposed to include strategic, operational, business cycle, damage, financial, and political risks. In addition, the threat of the global impact of pandemics, climate changes and the risk of cyber threats have increased.

The Group's strategic risks include competition in all sectors, the threat posed by new competing products, and any other actions of the Company's rivals that may affect the competitive situation. Another strategic risk is related to the ability to shift the strategic focus towards integrated and predictive eye care pathways and to succeed in R&D activities and to maintain a competitive product mix. The Group develops new technologies and any failure in the commercialization of individual development projects may result in the impairment of capitalized development expenses, with an impact on the result. Strategic risks in the Group's segments that require special expertise are also associated with the successful management and development of key human resources and the management of the subcontractor and supplier network. Strategic risks and the need for action are regularly monitored and assessed in connection with day-to-day management, monthly Group reporting, and annual strategy updates.

In terms of risks related to the operating environment, the range and likelihood of cyber threats have increased. When realized, a cyber threat can affect the continuity of Revenio Group's business, the Group's reputation, or lead to significant sanctions. Risks caused by cyber threats are prepared with technical, administrative and organizational information security development. Climate change is associated, for example, with an increase in extreme weather events, rising global temperatures, and sea level rise. The risks arising from these factors for the Group's business may include, among other things, disruptions in the supply chain. Moreover, global pandemics could have direct and indirect effects on Revenio Group's business, including an increased risk of personnel being incapacitated. Government mandated closures of factories or borders may weaken Revenio Group's operating environment and restrictions on the movement of people could hamper the sales and delivery of Revenio's products.

Corporate acquisitions and the purchase of assets with growth potential related to eye health are part of the Group strategy. The success of these acquisitions has a significant impact on the achievement of growth and profitability targets.

Acquisitions may also change the Group's risk profile. The Visionix transaction was completed on 28 May 2026. Revenio's ability to achieve the expected benefits from the Visionix transaction depends to a large extent on the timely and effective integration of Visionix's business, operations, technologies, products and personnel into Revenio's existing business.

Operational risks are associated with the retention and development of major customers, the operations of the distribution network, and success in extending the customer base and markets. Operational risks in the eye health sector that the Company specializes in include, in particular, factors related to expansion into new markets, such as various countries' national regulations of marketing authorizations for medical instruments and the related official decisions concerning the health care market. Success in eye health R&D projects launched in accordance with the strategy can also be classified as an operational risk. Furthermore, the global availability and cost challenges related to electronic components may cause operational risks.

The operational risks related to the manufacture, product development, and production control of medical instruments are estimated to be higher than average due to the sector's ambitious requirements concerning quality. Damage-related risks are covered by insurance. Property and business interruption insurance provides protection against risks in these areas. The business activities of the Group are covered by international liability insurance.

Financial risks can be further categorized into credit, interest rate, liquidity, and foreign exchange risks. The Board assesses financial risks and other financial matters in its monthly meetings, or more frequently, as necessary. If required, the Board provides decisions and guidelines for the management of financial risks including, for example, interest rate and currency hedging decisions. Liquidity risk can be affected by the availability of external financing, the development of the Group's credit standing, trends in business operations, and changes in the payment behavior of customers. Liquidity risks are monitored by means of cash forecasts, which are drawn up for periods of, at most, 12 months at a time.

Risks related to corporate responsibility are managed as part of the company's risk management process. Corporate responsibility is viewed through economic, environmental and social responsibility.

Revenio Group offers eye health diagnostics solutions under the iCare and Visionix brand. Reputational damage might have a negative impact on Revenio Group's business. Possible causes for reputational damage include cyber security or compliance challenges or notable delivery or product quality issues. Leakage of sensitive employee or customer data might also lead to reputational damage and notable financial consequences.

Revenio Group products are sold in more than 130 countries. Economic and political uncertainties, interest and inflation risks and the unstable trade and geopolitical situation may affect the demand for Revenio Group products. Revenio actively monitors political developments in different market areas from a risk management perspective. Developments in national government policies or changes to relevant legislation may have an impact on the Group's business.



Major shareholders on September 30, 2026*

		No. of shares	%
1	William Demant Invest A/S	7,260,971	24.89%
2	Caravelle Capital SAS	1,522,754	5.22%
3	Danske Invest	798,818	2.74%
4	Ilmarinen Mutual Pension Insurance Company	763,118	2.62%
5	SEB Funds	724,815	2.49%
6	Nordea Funds	493,732	1.69%
7	Varma Mutual Pension Insurance Company	446,116	1.53%
8	Marc Abitbol	442,658	1.52%
9	Elo Mutual Pension Insurance Company	405,000	1.39%
10	Schroders	380,000	1.30%
	Total	29,166,913	100%
	Foreign ownership		46.31%

* Monitor by Modular Finance AB. Compiled and processed ownership data from various public sources, including Euroclear Finland and Morningstar, and from direct shareholder disclosures. While all efforts have been made to secure as updated and complete information as possible, neither Modular Finance nor Revenio Group can guarantee the completeness or accuracy of the data.

Share-based incentive schemes

In June 2026, the Board of Directors of Revenio Group Oyj decided on two new long-term share-based incentive schemes. These comprise a restricted share plan (RSP) 2026–2028 for the Group's Leadership Team and other key employees, and a new performance period 2026–2028 under the performance share plan (PSP) for the CEO. The terms and conditions of the previously established schemes are presented in the Group's financial statements for the year ended 31 December 2025, and no material changes have been made to them.

Restricted Share Plan (RSP) 2026–2028

The grant date of the RSP 2026–2028 was in June 2026. The plan includes a two-year restriction period ending in the first half of 2028. Under the plan, the Company may grant fixed share awards to selected key employees. The awards will be paid after the end of the restriction period, subject to the condition that the participant's employment or service relationship remains in force at the time of payment (service condition).

The maximum number of gross shares to be awarded is approximately 175,000. The portion required to cover taxes and other applicable charges will be deducted from the award and paid in cash. The estimated total gross value of the plan is approximately EUR 2.275 million.

Performance Share Plan (PSP) 2026–2028

The grant date of the PSP 2026–2028 was in June 2026. Any awards earned under the plan will be paid in the first half of 2029. The performance criterion is growth in the Company's market capitalisation, and payment of the awards is subject to the achievement of the targets set by the Board of Directors.

If the targets are fully achieved, the maximum number of gross shares to be awarded is approximately 25,000, of which the portion required to cover taxes will be paid in cash. The estimated total gross value of the plan is approximately EUR 0.32 million.

Payment method and other terms

Under both plans, approximately 40% of the award will be paid in shares and approximately 60% in cash. The Company also reserves the right to settle the awards entirely in cash.

The share ownership policy applies to members of the Executive Leadership Team. Under the policy, each member is expected to retain at least half of the shares received under the incentive schemes until the value of their shareholding represents at least 50% of their annual gross base salary.

Key events in the review period

On 31 July 2026, Revenio provided an update on the progress of the Visionix integration and announced organisational changes in its US operations.

On 6 August 2026, Revenio's iCare and EyeCheq announced a strategic partnership and a minority investment.

On 12 August 2026, it was confirmed that Jukka Kainulainen would take up his position as the new Chief Financial Officer on 24 August 2026.

On 17 August 2026, Revenio's iCare DRSplus was included in an FDA-authorised AI solution for diabetic retinopathy screening.

On 21 September 2026, Revenio Group Corporation transferred a total of 10,146 of its own shares (REGV1) held by the company to the members of the Board of Directors as part of their remuneration. On 12 May 2026, the Annual General Meeting of Revenio Group Corporation resolved that approximately 40% of the Board members' annual remuneration would be paid in shares by transferring the company's own shares, up to a maximum of 11,200 shares in total, with the remaining approximately 60% paid in cash.

Events after the review period

As part of the financing arrangements for the Visionix acquisition, Revenio's Board of Directors resolved on 21 September 2026 to launch a fully underwritten rights issue of approximately EUR 80 million, in which Revenio offers its existing shareholders the opportunity to subscribe for up to 12,929,361 new shares at a subscription price of EUR 6.19 per share. Nine subscription rights entitle their holder to subscribe for four new shares. The subscription period commenced on 28 September 2026 and ended on 12 October 2026. The net proceeds from the rights issue will be used to repay the EUR 80 million bridge financing related to the Visionix acquisition.

The subscription period for the rights issue ended on 12 October 2026. A total of 12,929,361 new shares were offered for subscription in the rights issue. Revenio raised gross proceeds of approximately EUR 80.0 million through the rights issue, and the transaction costs related to the rights issue amounted to approximately EUR 2.9 million. The gross proceeds from the rights issue, less transaction costs, were recognised in the reserve for invested unrestricted equity. The new shares were registered with the Finnish Trade Register on 16 October 2026, as a result of which the total number of Revenio's shares increased from 29,166,913 to 42,096,274.

Revenio repaid the EUR 80 million bridge facility in full on 30 October 2026 using the net proceeds from the rights issue, in accordance with the financing agreement. Interest and fees related to the bridge financing totalled EUR 0.2 million and were paid in connection with the repayment.

As announced on November 9, 2026, Revenio Group had detected a cyberattack targeting the IT systems of its French subsidiary Visionix. The affected server contained internal IT service requests. Revenio immediately initiated measures to contain the attack to a local server, working in cooperation with the Group's internal experts and a leading external cybersecurity specialist.

Alternative key figures used in financial reporting

Revenio Group Corporation has adopted the guidelines of the European Securities and Market Authority (ESMA) on Alternative Performance Measures. In addition to the IFRS-based key figures, the Company will publish certain other generally used key figures that may, as a rule, be derived from the consolidated comprehensive profit & loss statement and balance sheet. The calculation of these figures is presented below. According to the Company's view, these key figures supplement the consolidated comprehensive profit & loss statement and balance sheet, providing a better picture of the company's financial performance and position.

Revenio Group's reported net sales are strongly affected by fluctuations in the exchange rate between the Euro and the US dollar. As an alternative key figure, the Company also presents net sales with the exchange rate effect eliminated.

Formulas

KEY FIGURE	PURPOSE	DEFINITION
Gross margin	Describes the margin after deducting direct material and services costs	Net sales – materials and services
Earnings before interest, income taxes, depreciation and amortization, EBITDA	Describes the company's operating performance before finance items, income taxes, depreciation and amortization	Operating profit + Depreciation and amortization
Earnings before interest, income taxes and amortization, EBITA	Describes the company's operating performance before finance items, income taxes and amortization	Operating profit + Amortization
Adjusted operating profit (EBIT)	Presents operating profit excluding items affecting comparability	Operating profit + items affecting comparability
Adjusted EBITDA	Presents EBITDA excluding items affecting comparability	EBITDA + items affecting comparability
Adjusted EBITA	Presents EBITA excluding items affecting comparability	EBITA + items affecting comparability
Return on investment (ROI)	Measures the return on invested capital	(Profit before income taxes + Finance expenses) / Invested capital (average)
Return on equity (ROE)	Measures the return on capital invested by shareholders	Profit for the financial year / Equity (average)
Equity ratio	Assesses solvency by measuring the proportion of equity relative to total assets	Equity / Total assets
Net leveraging (gearing)	Describes the debt burden relative to equity, taking cash assets into account	(Interest-bearing liabilities – Cash and cash equivalents) / Equity
Net debt / Adjusted EBITDA	Describes the debt burden relative to company's profitability	(Interest-bearing liabilities – Cash and cash equivalents) / (EBITDA 12 months + items affecting comparability 12 months)
Equity attributable to equity owners of the parent company per share	Describes the amount of equity per share	Equity / Number of shares
Growth in net sales, adjusted by the effect of exchange rates	Describes net sales growth excluding the effects of exchange rate changes	(Net sales excluding exchange rate effects – Net sales in the comparison period) / Net sales in the comparison period

Alternative key figures

GROSS MARGIN	7-9/2026	7-9/2025	1-9/2026	1-9/2025	1-12/2025
Net sales	58.8	25.9	125.4	78.5	109.7
Materials and services	-21.7	-7.4	-44.2	-21.8	-31.9
Gross margin	37.2	18.5	81.3	56.7	77.8

ADJUSTED EBITDA	7-9/2026	7-9/2025	1-9/2026	1-9/2025	1-12/2025
EBITDA	7.3	7.2	15.0	22.1	29.9
Items affecting comparability	3.0	0.2	9.8	0.7	1.1
Adjusted EBITDA	10.2	7.4	24.9	22.8	31.0

ADJUSTED EBITA	7-9/2026	7-9/2025	1-9/2026	1-9/2025	1-12/2025
EBITA	5.7	6.4	11.8	20.0	27.1
Items affecting comparability	3.0	0.2	9.8	0.7	1.1
Adjusted EBITA	8.7	6.6	21.7	20.7	28.3

EARNINGS BEFORE INTEREST, INCOME TAXES, DEPRECIATION AND AMORTIZATION, EBITDA	7-9/2026	7-9/2025	1-9/2026	1-9/2025	1-12/2025
Operating profit	3.6	6.0	8.4	18.7	25.4
Depreciation and amortization	3.7	1.1	6.7	3.4	4.5
EBITDA	7.3	7.2	15.0	22.1	29.9

EARNINGS BEFORE INTEREST, INCOME TAXES AND AMORTIZATION, EBITA	7-9/2026	7-9/2025	1-9/2026	1-9/2025	1-12/2025
Operating profit, EBIT	3.6	6.0	8.4	18.7	25.4
Amortizations	2.1	0.4	3.5	1.3	1.7
EBITA	5.7	6.4	11.8	20.0	27.1

ADJUSTED OPERATING PROFIT (EBIT)	7-9/2026	7-9/2025	1-9/2026	1-9/2025	1-12/2025
Operating profit, EBIT	3.6	6.0	8.4	18.7	25.4
Items affecting comparability	3.0	0.2	9.8	0.7	1.1
Adjusted operating profit, EBIT	6.5	6.2	18.2	19.4	26.5

RETURN ON INVESTMENT (ROI)	7-9/2026	7-9/2025	1-9/2026	1-9/2025	1-12/2025
Invested capital (equity + interest-bearing liabilities) average	265.1	121.0	265.1	121.0	123.8
Profit before income taxes	3.3	6.0	8.8	16.0	22.8
Finance expenses	0.6	0.3	2.8	1.7	3.0
Return on investment (ROI)	1.5%	5.3%	4.4%	14.6%	20.8%

RETURN ON EQUITY (ROE)	7-9/2026	7-9/2025	1-9/2026	1-9/2025	1-12/2025
Profit for the period	3.4	4.6	6.4	11.9	17.4
Equity (average)	152.3	108.3	134.9	108.3	111.2
Return on equity (ROE)	2.2%	4.2%	4.7%	11.0%	15.7%

EQUITY RATIO	7-9/2026	7-9/2025	1-9/2026	1-9/2025	1-12/2025
Equity	155.1	109.0	155.1	109.0	114.7
Total assets	480.1	137.0	480.1	137.0	150.6
Equity ratio	32.3%	79.6%	32.3%	79.6%	76.1%

NET LEVERAGING (GEARING)	7-9/2026	7-9/2025	1-9/2026	1-9/2025	1-12/2025
Interest-bearing liabilities	248.7	11.3	248.7	11.3	11.0
Cash and cash equivalents	17.2	14.4	17.2	14.4	26.2
Equity	155.1	109.0	155.1	109.0	114.7
Net leveraging (gearing)	149.3%	-2.8%	149.3%	-2.8%	-13.3%

NET DEBT / ADJUSTED EBITDA	7-9/2026	7-9/2025	1-9/2026	1-9/2025	1-12/2025
Interest bearing debt	248.7	11.3	248.7	11.3	11.0
Cash and cash equivalents	17.2	14.4	17.2	14.4	26.2
EBITDA, 12 months	35.7	32.4	35.7	32.4	29.9
Items affecting comparability	9.6	0.8	9.6	0.8	1.1
Net debt / Adjusted EBITDA *	5.1	-0.1	5.1	-0.1	-0.5

* Adjusted EBITDA in column Sep 30, 2026 is based on 2025 pro forma numbers and in column Sep 30, 2025 for historical 12-month values.

EQUITY ATTRIBUTABLE TO EQUITY OWNERS OF THE PARENT COMPANY PER SHARE	7-9/2026	7-9/2025	1-9/2026	1-9/2025	1-12/2025
Equity	155.1	109.0	155.1	109.0	114.7
Number of shares (1.000 pcs)	29,101.2	26,681.1	29,101.2	26,681.1	26,603.4
Equity attributable to equity owners of the parent company per share (EUR)	5.33	4.08	5.33	4.08	4.31

GROWTH IN NET SALES, ADJUSTED BY THE EFFECT OF EXCHANGE RATES	7-9/2026	1-9/2026
Reported net sales	58.8	125.4
Effect of exchange rates on net sales	-0.3	1.8
Net sales adjusted by the effect of exchange rates	58.5	127.2
Reported net sales for the comparison period	25.9	78.5
Growth in net sales, adjusted by the effect of exchange rates	125.5%	61.7%
Reported net sales growth	127.5%	59.8%
Difference, % points	-2.0%	1.9%

Accounting policies applied in the preparation of the Interim report

This interim report is not prepared in accordance with IAS 34. Revenio Group adheres to half-year reporting in accordance with the Securities Markets Act and, for the first three and nine months of the year, publishes interim reports to present key information on the Group's financial performance. The financial figures presented in this interim report are unaudited. The financial statement bulletin and the half-year report are drawn up in accordance with IAS 34 Interim Financial Reporting.

The Group has applied the following additions to its accounting policies:

Associates are entities over which the Group has significant influence but not control. Associates are accounted for using the equity method. Investments accounted for using the equity method are initially recognized at cost. The consolidated financial statements include the Group's share of the comprehensive income and changes in equity of equity accounted investees from the date on which significant influence commences until the date on which significant influence ceases.

Derivative contracts used to hedge interest rate risk are initially recognized at fair value on the date the derivative contract is entered into and are subsequently remeasured to fair value at the end of each reporting period. Changes in fair value are recognized in profit or loss and presented within finance income or finance expenses. In the statement of financial position, derivatives are presented within non-current liabilities under financial liabilities. Gains and losses arising from foreign currency hedging instruments are recognized in the same consolidated comprehensive profit & loss statement line items as the foreign exchange effects of the hedged items.

This report has been drawn up in accordance with the same reporting principles as the 2025 financial statements, except for the following amendments to the existing standards, which the Group has applied as of January 1, 2026:

IFRS 9 and IFRS 7 amendments, as well as Annual Improvements to IFRS Accounting Standards, Part 11.

In management's assessment, the adoption of these amendments has not had a material impact on the Group's financial statements.



REVENIO

Revenio Group Corporation: Interim report

January 1 – September 30, 2026, Tables



Consolidated comprehensive profit & loss statement

MEUR	7-9/2026	7-9/2025	1-9/2026	1-9/2025	1-12/2025
NET SALES	58.8	25.9	125.4	78.5	109.7
Other operating income	0.2	0.0	0.7	0.1	0.2
Materials and services	-21.7	-7.4	-44.2	-21.8	-31.9
Employee benefits expenses	-17.7	-6.1	-34.8	-19.3	-26.4
Depreciation, amortization, and impairment	-3.7	-1.1	-6.7	-3.4	-4.5
Other operating expenses	-12.4	-5.2	-32.1	-15.3	-21.7
OPERATING PROFIT	3.6	6.0	8.4	18.7	25.4
Net finance income and expenses	0.0	0.0	0.6	-2.7	-2.6
Share of the profit or loss of associates accounted for using the equity method	-0.3	0.0	-0.2	0.0	0.0
PROFIT BEFORE INCOME TAXES	3.3	6.0	8.8	16.0	22.8
Income taxes	0.1	-1.4	-2.4	-4.2	-5.4
PROFIT FOR THE PERIOD	3.4	4.6	6.4	11.9	17.4
Profit for the period attributable to:					
Owners of the parent	3.4	4.6	6.4	11.9	17.4
Non-controlling interests	0.0	0.0	0.0	0.0	0.0
Other comprehensive income items	-0.1	-0.2	0.2	-0.3	-0.2
TOTAL COMPREHENSIVE INCOME FOR THE PERIOD	3.3	4.4	6.6	11.5	17.2
Total comprehensive income attributable to:					
Owners of the parent	3.3	4.4	6.6	11.5	17.2
Non-controlling interests	0.0	0.0	0.0	0.0	0.0
Earnings per share, EUR	0.116	0.173	0.231	0.446	0.655

Consolidated balance sheet

MEUR	30.9.2026	30.9.2025	31.12.2025
ASSETS			
NON-CURRENT ASSETS			
Goodwill	184.3	62.8	62.9
Other intangible assets	129.4	22.6	23.3
Property, plant and equipment	9.6	2.2	2.1
Right-of-use assets	9.4	4.3	5.0
Other non-current financial assets	3.0	0.4	0.5
Investments accounted for using the equity method	22.4	0.0	0.0
Other receivables	2.3	0.1	0.3
Deferred tax assets	17.9	2.7	3.7
TOTAL NON-CURRENT ASSETS	378.3	95.2	97.8
CURRENT ASSETS			
Inventories	47.4	10.1	10.8
Trade and other receivables	37.2	17.2	15.8
Cash and cash equivalents	17.2	14.4	26.2
TOTAL CURRENT ASSETS	101.8	41.8	52.8
TOTAL ASSETS	480.1	137.0	150.6

MEUR	30.9.2026	30.9.2025	31.12.2025
EQUITY AND LIABILITIES			
EQUITY			
Share capital	5.3	5.3	5.3
Fair value reserve	-0.4	-0.4	-0.4
Reserve for invested unrestricted capital	84.7	52.0	52.0
Other reserves	0.3	0.3	0.3
Retained earnings	66.7	53.8	59.4
Translation difference	-0.1	-0.5	-0.3
Treasury shares	-1.3	-1.6	-1.6
Total equity attributable to owners of the parent	155.1	109.0	114.7
Non-controlling interests	0.0	0.0	0.0
TOTAL EQUITY	155.1	109.0	114.7
LIABILITIES			
NON-CURRENT LIABILITIES			
Deferred tax liabilities	20.2	3.4	3.5
Interest-bearing and other non-current liabilities	116.3	3.9	3.0
Lease liabilities	6.4	3.1	3.6
TOTAL NON-CURRENT LIABILITIES	143.0	10.4	10.2
CURRENT LIABILITIES			
Trade and other payables	48.4	11.5	19.3
Provisions	3.3	0.5	0.8
Interest-bearing current liabilities	127.4	4.2	4.2
Lease liabilities	2.9	1.4	1.5
TOTAL CURRENT LIABILITIES	182.0	17.6	25.8
TOTAL LIABILITIES	325.0	28.0	35.9
TOTAL EQUITY AND TOTAL LIABILITIES	480.1	137.0	150.6

Consolidated statement of changes in equity

MEUR	Share capital	Reserve for invested unrestricted equity	Other reserves	Retained earnings	Translation difference	Treasury shares	Total equity
Equity 1 Jan 2026	5.3	52.0	-0.1	59.4	-0.3	-1.6	114.7
Dividend distribution	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Issue of share capital	0.0	32.9	0.0	0.0	0.0	0.0	32.9
Disposal and purchase of treasury shares	0.0	-0.2	0.0	0.0	0.0	0.2	0.0
Other direct entries to retained earnings	0.0	0.0	0.0	0.9	0.0	0.0	0.9
Profit for the period	0.0	0.0	0.0	6.4	0.0	0.0	6.4
Other comprehensive income	0.0	0.0	0.0	0.0	0.1	0.0	0.2
Total equity attributable to owners of the parent	5.3	84.7	-0.1	66.7	-0.1	-1.3	155.1
Non-controlling interests	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total equity 30 September 2026	5.3	84.7	-0.1	66.7	-0.1	-1.3	155.1

MEUR	Share capital	Reserve for invested unrestricted equity	Other reserves	Retained earnings	Translation difference	Treasury shares	Total equity
Equity 1 Jan 2025	5.3	52.1	-0.1	52.2	-0.1	-1.7	107.7
Dividend distribution	0.0	0.0	0.0	-10.6	0.0	0.0	-10.6
Disposal and purchase of treasury shares	0.0	-0.1	0.0	0.0	0.0	0.1	0.0
Other direct entries to retained earnings	0.0	0.0	0.0	0.4	0.0	0.0	0.4
Profit for the period	0.0	0.0	0.0	11.9	0.0	0.0	11.9
Other comprehensive income	0.0	0.0	0.0	0.0	-0.3	0.0	-0.3
Total equity 30 September 2025	5.3	52.0	-0.1	53.8	-0.5	-1.6	109.0

Consolidated cash flow statement

MEUR	7-9/ 2026	7-9/ 2025	1-9/ 2026	1-9/ 2025	1-12/ 2025
CASH FLOW FROM OPERATIONS					
Profit for the period	3.4	4.6	6.4	11.9	17.4
Adjustments:					
Depreciation, amortization, and impairment	3.7	1.1	6.7	3.4	4.5
Other non-cash items	0.6	0.1	-0.2	1.0	1.3
Interest and other financial expenses	0.6	0.4	1.8	3.2	3.1
Interest income and other finance income	-0.4	-0.4	-2.3	-0.5	-0.6
Income taxes	-0.1	1.4	2.4	4.2	5.4
Other adjustments	0.0	0.0	-0.1	-0.1	-0.1
Change in working capital:					
Changes in sales and other receivables	-1.1	-0.6	-4.4	1.2	1.3
Changes in inventory	-0.1	-0.4	0.8	0.0	-0.7
Changes in trade and other payables	2.1	-1.7	-3.7	-4.1	3.5
Change in working capital, total	1.0	-2.7	-7.3	-2.9	4.1
Interest paid	-1.5	-0.1	-2.4	-0.3	-0.4
Interest received	0.0	0.0	0.1	0.1	0.1
Income taxes paid	-1.6	-1.5	-5.3	-5.5	-4.6
NET CASH FLOW FROM OPERATING ACTIVITIES	5.5	3.0	-0.3	14.4	30.2
CASH FLOW FROM INVESTING ACTIVITIES					
Acquisitions of subsidiaries less cash and cash equivalents at acquisition time	0.4	0.0	-166.1	0.0	0.0
Purchase of property, plant and equipment	-0.6	-0.2	-1.1	-0.6	-1.1
Purchase of intangible assets	-0.5	-0.8	-2.1	-2.0	-3.1
Investments in other receivables	0.0	0.0	0.0	0.0	-1.1
Dividends received	1.1	0.0	1.1	0.0	0.0
NET CASH FLOW FROM INVESTING ACTIVITIES	0.3	-1.1	-168.3	-2.6	-5.2

MEUR	7-9/ 2026	7-9/ 2025	1-9/ 2026	1-9/ 2025	1-12/ 2025
CASH FLOW FROM FINANCING ACTIVITIES					
Repayments of loans	-6.0	-1.1	-70.2	-3.2	-4.2
Proceeds from borrowings	0.0	0.0	229.0	0.0	0.0
Dividends paid	0.0	0.0	0.0	-10.6	-10.6
Payments of lease agreement liabilities	-1.0	-0.6	-1.7	-1.3	-1.7
NET CASH FLOW FROM FINANCING ACTIVITIES	-7.0	-1.6	157.1	-15.1	-16.6
Net change in cash and credit accounts	-1.2	0.3	-11.5	-3.3	8.4
Cash and cash equivalents at beginning of period	17.8	14.0	26.2	20.7	20.7
Effect of exchange rates	0.6	0.1	2.5	-3.0	-2.9
Cash and cash equivalents at end of period	17.2	14.4	17.2	14.4	26.2

Preliminary Purchase Price Allocation for the Visionix acquisition

The identifiable assets acquired and liabilities assumed have been measured at their acquisition-date fair values. Any excess of the purchase consideration over the identifiable net assets acquired has been recognised as goodwill. The purchase price allocation is preliminary as the determination of the fair values of the identifiable assets acquired and liabilities assumed is still incomplete at the reporting date. In particular, the amounts allocated to intangible assets and the resulting goodwill are provisional. Amounts may be adjusted within 12 months of the acquisition date.



The following table gives the initial fair value of the net assets acquired and the initial goodwill arising from the acquisition at the time of acquisition:

Acquisition cost calculation MEUR	
Acquisition cost during the review period	226.9
Assets	
Non-current assets	
Intangible assets	108.1
Tangible assets	13.0
Deferred tax assets	12.1
Other receivables	2.1
Investments	22.6
Total non-current assets	157.9
Current assets	
Inventories	33.2
Trade and other receivables	23.7
Cash and cash equivalents	10.9
Total current assets	67.8
Total assets	225.7
Liabilities	
Non-current liabilities	
Financial liabilities	58.4
Lease liabilities	4.7
Deferred tax liabilities	17.2
Other non-current liabilities	3.1
Total non-current liabilities	83.4
Current liabilities	
Lease liabilities	1.8
Trade and other payables	34.3

Acquisition cost calculation MEUR	
Total current liabilities	36.2
Total liabilities	119.6
Net (liabilities) / assets	106.1
Goodwill	120.7
Purchase consideration	226.9
Cash flow	
Consideration paid during the reporting period	-177.1
Closing cash	10.9
Total cash flow	-166.2

Purchase consideration (MEUR)	
Cash paid	177.1
Ordinary shares issued	33.4
Deferred consideration	16.4
Total purchase consideration	226.9

The fair value of the 2,485,797 shares issued as part of the consideration paid was based on the closing share price on 28 May 2026 of EUR 13.44 per share. Issue costs of EUR 484.2 thousand, which were directly attributable to the issue of the shares, have been netted against the deemed proceeds in reserve for invested unrestricted equity.

Deferred consideration with nominal value of EUR 17,250 thousand falls due for payment one year after the completion of the transaction and has been discounted in purchase consideration.

The fair values of the identifiable assets and liabilities presented above are preliminary and may be adjusted during the purchase price allocation measurement period (up to 12 months from the acquisition date) in accordance with IFRS 3. The Group has engaged external valuation experts to determine the fair values of the identified intangible assets.

The allocation of goodwill has not yet been finalized. The goodwill arises from the acquired company's market position and broader geographical reach, particularly in the EMEA region and the United States; the synergies expected to result from combining Revenio's and Visionix's complementary businesses; the standalone growth prospects of Visionix's business; its skilled workforce; and the going-concern value of the established business.

Acquisition-related costs

Direct transaction costs amounted to approximately EUR 6.1 million during the nine-month period ended 30 September 2026 and were recognized in profit or loss (of which EUR 0.0 million was recognized during the interim period ended 30 September 2026). The costs comprise advisory, legal, due diligence and other expenses directly attributable to the acquisition.

Net sales and profit impact

The acquired business contributed EUR 47.6 million to the Group's net sales and EUR 2.9 million to the Group's net profit for the period from 28 May to 30 September 2026. If the acquisition had taken place on 1 January 2026, management estimates that the Group's net sales for the nine-month period would have been approximately EUR 181.0 million and profit for the financial year after income tax approximately EUR 2.0 million.

Net sales breakdown

Net sales by geographical area MEUR	7-9/2026	7-9/2025	Change, %	1-9/2026	1-9/2025	Change, %	2025	Pro forma 2025
North America	19.7	14.1	39.4%	47.3	38.7	22.2%	55.0	89.8
EMEA and LATAM	34.3	8.0	330.1%	64.5	26.3	145.7%	36.7	139.0
APAC	4.8	3.8	28.1%	13.5	13.5	0.2%	18.0	24.0
Total	**58.8**	**25.9**	**127.5%**	**125.4**	**78.5**	**59.8%**	**109.7**	**252.8**

Note: The unaudited pro forma financial information has been prepared to illustrate how the Visionix Transaction and related financing would have affected Revenio's consolidated comprehensive profit & loss statement had they been completed on 1 January 2025.

Intangible assets and property, plant and equipment

Intangible assets JAN 1 - SEP 30, 2026	Goodwill	Other intangible assets	Total
Acquisition cost Jan 1	62.9	35.3	98.2
Increases during the period	0.0	2.1	2.1
Acquired businesses	120.7	114.0	234.7
Translation differences	0.7	0.2	0.9
Acquisition cost Sep 30	184.3	151.6	335.9
Accumulated amortization Jan 1	0.0	-12.0	-12.0
Accumulated amortization of acquired businesses	0.0	-6.3	-6.3
Amortization during the year	0.0	-3.5	-3.5
Translation differences	0.0	-0.3	-0.3
Accumulated amortization Sep 30	0.0	-22.1	-22.1
Book value Sep 30	184.3	129.4	313.8
Book value Jan 1	62.9	23.3	86.2

Property, plant and equipment JAN 1 - SEP 30, 2026	Buildings	Land	Machinery and equipment	Advance payments and purchases in progress	Total
Acquisition cost Jan 1	0.0	0.0	8.4	0.1	8.4
Increase during the period	0.2	0.6	1.2	0.4	2.3
Acquired businesses	0.7	1.7	18.4	0.0	20.8
Translation differences	0.0	0.0	0.1	0.0	0.1
Decreases during the period	0.0	0.0	0.0	-0.1	-0.1
Acquisition cost Sep 30	0.9	2.3	28.0	0.3	31.5
Accumulated depreciation Jan 1	0.0	0.0	-6.3	0.0	-6.3
Accumulated depreciation of acquired businesses	-0.3	0.0	-13.9	0.0	-14.1
Depreciation during the year	-0.2	0.0	-1.2	0.0	-1.4
Translation differences	0.0	0.0	-0.1	0.0	-0.1
Accumulated depreciation Sep 30	-0.5	0.0	-21.5	0.0	-21.9
Book value Sep 30	0.4	2.6	6.6	0.3	9.6
Book value Jan 1	0.0	0.0	2.1	0.1	2.1

Lease agreements

Right-of-use assets JAN 1 - SEP 30, 2026	Business premises	Cars	Devices	Total
Acquisition cost Jan 1	6.5	1.1	0.2	7.8
Increase during the period	0.1	0.8	0.0	0.9
Acquired businesses	4.2	1.1	0.0	5.3
Translation differences	0.1	0.0	0.0	0.1
Decreases during the period	-0.1	-0.5	-0.1	-0.7
Acquisition cost Sep 30	10.7	2.5	0.2	13.3
Accumulated depreciation Jan 1	-2.0	-0.7	-0.1	-2.8
Depreciation during the year	-1.4	-0.4	0.0	-1.9
Translation differences	0.1	0.0	0.0	0.1
Decreases during the period	0.1	0.5	0.0	0.6
Accumulated depreciation Sep 30	-3.2	-0.7	-0.1	-3.9
Book value Sep 30	7.6	1.8	0.1	9.4
Book value Jan 1	4.5	0.3	0.1	5.0



Equity

Share issue

As part of the arrangements for the Visionix transaction, Revenio carried out a directed share issue to the sellers, in which 2,485,797 new Revenio shares were issued and subscribed for by the sellers. The new shares were paid for through a contribution in kind by transferring shares in Visionix to Revenio. The new shares were registered with the Trade Register on May 29, 2026, and the subscription price was recognized in Revenio's invested unrestricted equity reserve (SVOP) at the share price on the completion date of the transaction.

As part of the financing arrangements for the Visionix acquisition, Revenio's Board of Directors resolved on 21 September 2026 to launch a fully underwritten rights issue of approximately EUR 80 million, in which Revenio offered its existing shareholders the opportunity to subscribe for up to 12,929,361 new shares at a subscription price of EUR 6.19 per share. Nine subscription rights entitled their holder to subscribe for four new shares. The subscription period commenced on 28 September 2026 and ended on 12 October 2026. Further information is provided in the section Events after the review period.

Changes in the number of shares and their impact on equity	Number of shares	Share capital	Reserve for invested unrestricted equity	Treasury shares	Total
Jan 1, 2026	26,681,116	5.3	52.0	-1.6	55.8
Transfer of treasury shares March 17, 2026			-0.0	0.0	0.0
Directed share issue May 28, 2026	2,485,797		32.9		32.9
Transfer of treasury shares on September 21, 2026			-0.2	0.2	0.0
Sep 30, 2026	29,166,913	5.3	84.7	-1.3	88.7

Following the transfer of treasury shares on 21 September 2026, the Company holds 65,704 of treasury shares at the end of the review period.

Dividend

The Annual General Meeting held on May 12, 2026, resolved that no dividend would be distributed for the financial year 2025. In accordance with the terms of the share purchase agreement for the acquisition of Visionix, Revenio has undertaken not to propose the distribution of dividends until the deferred purchase price payable to the sellers has been paid in full. The deferred purchase price falls due to payment one year after the completion of the transaction.

Earnings per share

	JAN 1 – SEP 30, 2026	JAN 1 - SEP 30, 2025	JAN 1 - DEC 31, 2025
Profit for the period	6.4	11.9	17.4
Profit for the period attributable to owners of parent	6.4	11.9	17.4
Weighted average number of outstanding shares during the financial period (treasury shares deducted), qty	27,758,516	26,602,985	26,603,425
Earnings per share	0.231	0.446	0.655

The Group's interest-bearing debt and derivatives at end of period

Financial instrument	Use	Initial amount	Principal out-standing	Book value	Year when granted
Loan from financial institution	Acquired businesses	130.0	124.0	124.0	2026
Bridge financing	Acquired businesses	80.0	80.0	79.9	2026
Vendor loan	Acquired businesses	17.3	17.3	16.4	2026
Credit facility	Acquired businesses	19.0	19.0	18.9	2026
Interest rate swap	Hedging of interest rate risk	65.0	65.0	0.0	2026

To finance the Visionix acquisition, the Group drew a total of EUR 220 million under the financing agreement in May 2026. The financing consists of an EUR 130 million term loan, an EUR 80 million bridge facility, and an EUR 10 million revolving credit facility for general corporate purposes. In addition, the acquisition includes a EUR 17 million vendor loan arrangement. In addition to the revolving credit facility included in the new financing agreement, the Group has a EUR 10 million revolving credit facility for general corporate purposes, of which EUR 1 million remained undrawn as of 30 September 2026.

The original maturity of the term loan and the revolving credit facility is four years from the signing date of the financing agreement, and each may be extended by 12 months with the lender's consent. The term loan is amortized semi-annually. The bridge facility is a bullet loan. The original maturity of the bridge facility is six months from its drawdown date of 28 May 2026, and it may, at Revenio's option, be extended by up to six months.

Under the financing agreement, the Group is required to use the net proceeds from the rights offering planned to be completed during the second half of 2026 to repay the bridge facility until the bridge facility, together with all accrued interest, fees and expenses, has been repaid in full. If the rights offering has not been completed by 28 May 2027 and the funds committed under the previously announced underwriting commitments have not been received, or evidence thereof has not been provided in accordance with the financing agreement, Nordea shall be entitled to cancel its financing commitments and declare all loans drawn under the financing agreement immediately due and payable.

The financing agreement includes a net leverage covenant, pursuant to which the ratio of the Group's net debt to adjusted EBITDA (as defined in the financing agreement) must not exceed 4.50:1 on the testing dates of 31 December 2026 and 31 March 2027, and 3.50:1 on each quarter-end date thereafter. In accordance with the terms of the financing agreement, the covenant level may be temporarily increased in connection with certain acquisitions.

The financing agreement further contains representations, undertakings and security arrangements customary for financing arrangements of this nature, as well as customary provisions relating to change of control, illegality and sanctions, including mandatory prepayment events and events of default.

Repayments of financial liabilities

During the review period, EUR 6.0 million of the EUR 130 million term loan was repaid.

Derivative instruments

During the review period, Revenio entered into an interest rate swap with a notional amount of EUR 65 million in relation to the EUR 130 million term loan under the new financing agreement. The interest rate swap is measured at fair value through profit or loss. The fair value of the interest rate swap is determined as the present value of future cash flows, calculated using observable market interest rates. Changes in fair value are recognized in finance income or finance expenses. The interest rate swap is presented in the statement of financial position under non-current financial liabilities.

Classification of financial liabilities

SEP 30, 2026	At fair value through profit or loss	Amortized cost	Book value	Fair value
Interest-bearing non-current liabilities	0.0	119.3	119.3	119.3
Other non-interest bearing non-current liabilities	0.0	3.5	3.5	3.5
Interest-bearing current liabilities *	0.0	130.3	130.3	130.3
Trade payables and other non-interest bearing current liabilities	0.0	48.4	48.4	48.4

DEC 31, 2025	At fair value through profit or loss	Amortized cost	Book value	Fair value
Interest-bearing non-current liabilities	0.0	5.3	5.3	5.3
Other non-interest bearing non-current liabilities	0.0	1.3	1.3	1.3
Interest-bearing current liabilities	0.0	5.7	5.7	5.7
Trade payables and other non-interest bearing current liabilities	0.0	18.3	18.3	18.3

* Includes a vendor loan of EUR 16.4 million.

Maturity analysis of contractual liabilities

SEP 30, 2026	Under 1 year	1-5 Years	Over 5 years	Total cash flow
Trade payables and other non-interest bearing debt	48.4	3.5	0.0	51.9
Lease liabilities	2.9	5.8	0.6	9.4
Interest-bearing debt	127.4	112.7	0.2	240.2

DEC 31, 2025	Under 1 year	1-5 Years	Over 5 years	Total cash flow
Trade payables and other non-interest bearing debt	18.3	0.5	0.0	18.8
Lease liabilities	1.5	3.6	0.0	5.1
Interest-bearing debt	4.3	1.7	0.0	6.0

Appendix 1: Unaudited Pro Forma 2025 Financial Information

On May 28, 2026, Revenio Group Oyj completed the acquisition of LT International SAS, the parent company of Visionix International Group (the “Visionix Transaction”). To illustrate the effects of the Visionix Transaction and related financing on Revenio’s financial information and to facilitate comparability between reporting periods, Revenio presents in this interim report unaudited pro forma financial information for the financial year ended December 31, 2025.

The unaudited pro forma financial information has been prepared to illustrate how the Visionix Transaction and related financing would have affected Revenio’s consolidated comprehensive profit & loss statement had they been completed on January 1, 2025.

The pro forma financial information is presented for illustrative purposes only and, because of its nature, it addresses a hypothetical situation. Therefore, it is not necessarily indicative of what Revenio’s results of operations would have actually been had the Visionix Transaction and related financing been completed on the date indicated, nor is it meant to be indicative of any anticipated future results of operations that will be experienced going forward.

The unaudited pro forma financial information has been prepared based on the historical consolidated financial information of Revenio and the historical consolidated financial information of Visionix, and adjusted with impacts from the Visionix Transaction and related financing on a pro forma basis. Pro forma financial information has not been adjusted to reflect any potential cost savings, synergy benefits or future integration costs that are expected to be generated or may be incurred as a result of the Visionix Transaction.

Revenio has published the unaudited pro forma financial information for the six months ended June 30, 2026 and for the financial year ended December 31, 2025, including the basis of preparation for the pro forma information, in the rights issue Offering Circular dated September 25, 2026 which is available on the company’s website at www.reveniogroup.fi/investors/rights_offering_2026.



Pro forma key figures

MEUR, unless otherwise indicated	1-12/2025
Net sales	252.8
Gross margin	152.9
Gross margin-%	60.5%
EBITDA	35.7
EBITDA-%	14.1%
Adjusted EBITDA	45.3
Adjusted EBITDA-%	17.9%
EBITA	29.8
EBITA-%	11.8%
Adjusted EBITA	39.3
Adjusted EBITA-%	15.6%
Operating profit	21.6
Profit for the period	3.2

2025 pro forma net sales by product line

Product line	M€	Share of total
Refraction systems		< 10%
Imaging		10% - 20%
Tonometers		10% - 20%
OCT		10% - 20%
Standard equipment, finishing and other		10% - 20%
Multimodal devices		10% - 20%
Services, software and consumables *		~20%
Total	**253**	**100 %**

* Consumables, including probe sales

Audiocast and teleconference

Revenio will hold a live audiocast and teleconference call for analysts, investors, and media in English at 3.00 p.m. (EET) on November 12, 2026. CEO Jouni Toijala and CFO Jukka Kainulainen will present the Interim report.

The audiocast can be watched live at:
revenio.events.inderes.com/q3-2026

To ask questions, please join the teleconference by registering using the following link:
events.inderes.com/revenio/q3-2026/dial-in

Phone numbers and the conference ID to access the conference will be provided after registration. To ask a question, please press #5 on your telephone keypad to enter the queue.

A recording of the audiocast will be published on www.reveniogroup.fi/en after the event.

Revenio Group Corporation
Board of Directors

For further information, please contact

CEO **Jouni Toijala**
jouni.toijala@revenio.fi

CFO **Jukka Kainulainen**
jukka.kainulainen@revenio.fi

+358 9 8775 1150

Distribution

Nasdaq Helsinki Oy
Financial Supervisory Authority (FIN-FSA)
Principal media
www.reveniogroup.fi/en



Revenio Group in brief

Revenio is a leading turnkey solutions provider in the global eye care market. The group offers fast, user-friendly, and reliable tools for diagnosing a wide variety of eye diseases. Revenio's solutions include e.g. tonometers, fundus imaging devices, optical coherence tomography (OCT), perimeters, multimodal devices, refraction systems, and software solutions under iCare and Visionix.

In May 2026, Revenio joined forces with Visionix, creating the most innovative, creative and comprehensive entity serving eye care professionals across optometry, optical retail and ophthalmology. In 2025, the Group's net sales totaled EUR 109.7 million, with an operating profit of EUR 25.4 million. In 2025, the Group's pro forma net sales totaled EUR 252.8 million, with a pro forma adjusted EBITDA of EUR 45.3 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.



REVENIO

www.reveniogroup.fi/en
ir@revenio.fi